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Introduction 
Tetanus was well known to the ancient 
physicians of Egypt and Greece, but since 
institution of the active immunization in 
1940, it has become an old forgotten disease 
in developed countries.1 Tetanus is a 
nervous system disorder characterized by 
prolonged contraction of the skeletal 
muscles. The disease is caused by 
tetanospasmin, a neurotoxin produced by the 
anaerobic bacterium Clostridium tetani.   
 
Case Report 
A 74-year-old Caucasian female 
presented to the emergency department 
complaining of trismus.  The patient had not 
been evaluated by a physician for several 
years.  Her symptoms started 10 days prior 
with difficulty opening her mouth, 
generalized muscle stiffness, and episodic 
muscle spasms. She denied fever and chills, 
was not taking any medications, and had no 
history of alcohol or illicit drug use. She did 
not remember ever receiving tetanus 
vaccination. 
On physical examination, the patient was 
unable to open her mouth more than 1 cm 
and the masseter muscle was contracted.  
She had a generalized increase in muscle 
tone and episodic painful muscle spasms 
involving the entire body.  Multiple scars   
in different healing stages over the lower 
extremities had been caused by scratches 
from her 13 cats.   
The diagnosis of generalized tetanus was 
suspected.     Five  hundred  units  of  human  
 
 
 
tetanus immunoglobulin were given 
intramuscularly and active immunization 
was started.  Although there was no active 
wound infection, the patient was started on 
intravenous metronidazole.  Muscle spasms 
and rigidity were controlled with a 
scheduled dose of intravenous diazepam. 
Over the next three weeks, the patient’s 
symptoms gradually improved, and she was 
discharged to a skilled nursing facility.  
 
Epidemiology   
The incidence of tetanus in developed 
countries dropped dramatically since 1940 
mainly due to the widespread use of active 
immunization.1  Better hygiene and wound 
care also have played a major role.  The 
annual incidence of tetanus in the US has 
fallen from 4 to 0.2 per million since 1947.1 
The decline in incidence was accompanied 
by a decrease in mortality from 50 to 30%.   
Between 1998 and 2000, the annual 
incidence of tetanus was 0.16 cases/million 
representing an average of 43 cases per 
year.2 The majority of cases were in patients 
older than 60 years, reflecting the waning of 
immunity with age or inadequate 
immunization of the elderly.1 Injection drug 
abuse and the increase of non-immunized 
immigrants are responsible for most cases of 
tetanus in younger individuals aged 25 to 59.    
According to the CDC2, 15% of cases of 
tetanus in the US occurred in intravenous 
drug users.  
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Acute injuries account for 70 to 80% of 
US cases; 23% of cases are associated with 
chronic decubitus ulcers, gangrene, burns 
and abcesses.1  About 7% of cases have no 
apparent source.  Neonatal tetanus is rare in 
the US.1,2   
Tetanus is common in developing 
countries. The worldwide incidence is about 
1,000,000 cases per year.3,4  It is a major 
cause of death especially in neonates. 
Tetanus accounted for 300,000 deaths in 
2000, including 200,000 neonatal deaths.5 
 
Pathogenesis and Pathology 
Clostridium tetani is an obligatory gram 
positive anaerobic bacillus. The bacteria are 
usually found in contaminated soil and 
animal gut in the sporiform phase.  When 
these spores contaminate a wound, they 
germinate under anaerobic conditions, 
transform into a rod-shaped bacterium, and 
produce tetanospasmin.  Tetanospasmin is 
an exotoxin produced by mature bacteria, 
then cleaved intracellularly into light and 
heavy chains before exocytosis. The heavy 
chain appears to mediate binding to cell 
surface and transport proteins, while the 
light chain is responsible for the clinical 
manifestations of tetanus.1  
After its excretion, tetanospasmin gains 
entry into the central nervous system (CNS), 
both locally and distally, via the presynaptic 
terminals of lower motor neurons.  
Tetanospasmin is transported intra-axonally 
in a retrograde fashion to the cell body, the 
ventral horns of the spinal cord, and to the 
motor nuclei of the cranial nerves where it 
exerts its major pathogenic action.  After 
reaching the spinal cord and the brain stem, 
tetanospasmin binds tightly and irreversibly 
to specific receptors, inhibiting the release 
of inhibitory neurotransmitters (glycine and 
γ-amino-butyric acid) from presynaptic 
inhibitory neurons.   
The net effect is the disinhibition of 
motor excitatory neurons resulting in 
increased muscle tone and painful spasm. 
The autonomic nervous system also is 
affected, manifested by a hypersympathetic 
state due to failure to inhibit the adrenal 
release of catecholamine.  Tetanospasmin 
interferes with pre-synaptic acetylcholine 
release at the neuromuscular junction and 
disinhibits sympathetic reflexes at the spinal 
level.1 The inhibitory effect of 
tetanospasmin is irreversible.  Recovery 
requires the growth of new axonal nerve 
terminals in 4 to 6 weeks. Clostridium tetani 
produces another toxin called tetanolysin 
that apparently has no pathogenic role.1 
  
Clinical Features 
The incubation period of tetanus usually 
lasts between 3 and 21 days with a range of 
one day to several months.1 A correlation 
exists between the distance of the injury 
from the CNS and the duration of the 
incubation period.1,5 The closer the distance, 
the shorter the incubation period. Both the 
incubation period and the time of onset 
(time from the first symptom to the first 
generalized spasm) inversely correlate with 
prognosis.1 
Tetanus has four clinical forms: 
generalized, localized, cephalic, and 
neonatal.  Generalized tetanus is the most 
common and severe.  The generalized form 
typically starts with spasm of the masseter 
muscles, causing trismus or “lockjaw” and 
increased tone of the orbicularis oris 
resulting in the characteristic “risus 
sardonicus”.  The patient experiences diffuse 
spasms involving muscle groups in the neck, 
back, abdomen, and extremities. These 
spasms are painful, intermittent, and 
unpredictable. They often are triggered by 
noise and light.  
Patients with generalized tetanus 
typically have symptoms of autonomic 
overactivity that manifest as sweating, 
tachycardia, cardiac arrhythmia, labile 
hypertension or hypotension, and fever. 
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Respiratory muscles also are affected 
causing periods of apnea. During 
generalized tetanic spasms, patients 
characteristically clench their fists, arch their 
back, flex their arms while extending their 
legs, and become apneic.1 Death is due to 
respiratory failure or to autonomic 
dysfunction.  Recurrent tetanus may occur if 
the patient is not immunized since the 
infection does not confer immunity. 
Recovery is typically 2 to 6 weeks.   
 Localized tetanus is usually a prodrome 
of the generalized form.  It presents with 
localized rigidity and spasm of a muscle 
group near the site of injury.  Subsequently, 
patients develop generalized tetanus.  In 
some cases, localized disease reflects partial 
immunity with resolution of the spasms 
without generalization.6 Cephalic tetanus is 
a form of localized tetanus involving the 
cranial nerves in a patient with head and 
neck injuries.1 
Neonatal tetanus is related to the 
inadequate use of aseptic techniques in non-
immunized mothers.  It usually occurs 
within 14 days after birth.1,7  Infants present 
with generalized weakness and failure to 
nurse, followed by rigidity and spasms. 
Mortality exceeds 90%. Apnea and sepsis 
are the leading causes of death.   
 
Diagnosis  
The diagnosis of tetanus is based on 
clinical symptoms and a high index of 
suspicion in susceptible individuals.1 
Anaerobic cultures from the wound are 
usually negative.  A positive culture does 
not confirm the diagnosis.  Anti-tetanus 
antibodies are undetectable in the majority 
of patients with tetanus. However, the 
presence of antibodies at low titer does not 
confer immunity and cannot be used to rule 
out the disease.  Electroencephalography 
and electromyography can be helpful in 
ruling out other conditions. 
 
Differential Diagnosis 
 Strychnine poisoning may produce a 
clinical syndrome similar to tetanus.  
Toxicologic screen of urine and blood 
should be performed if a suspicious injection 
is suspected or the history is not typical for 
tetanus (e.g., no injury or adequate 
immunization).  The treatment of tetanus 
and strychnine poisoning is similar.  
Trismus due to dental infection may be 
confused with cephalic tetanus. Drug 
induced dystonia and malignant neuroleptic 
syndrome can mimic tetanus. 
 
Treatment 
The treatment of patients with tetanus 
requires a multidisciplinary approach in the 
intensive care unit.1 The mainstay of 
treatment consists of eliminating the source 
of toxin production, neutralizing unbound 
toxin, and managing symptoms and 
complications. 
 
Halting toxin production 
Wound debridement is important to 
eliminate the source of toxin production.  
All foreign bodies, including spores and 
necrotic tissue, should be removed. 
Metronidazole and penicillin G are the drugs 
of choice, but studies have shown better 
outcomes with metronidazole.1,8 Intravenous 
metronidazole should be given initially at a 
dose of 15mg/kg followed by 20 to 30 
mg/kg/day intravenously for 7 to 14 days or 
until there is no visible sign of active local 
infection.1  Alternatives include cefazolin, 
cefuroxime, and ceftriaxone. 
 
Neutralizing of unbound toxin 
Tetanospasmin is bound irreversibly to 
tissues and only unbound toxin is available 
for neutralization. Passive immunization 
with human tetanus immune globulin 
(HTIG) shortens the course of tetanus and 
improves survival.   A  dose of  500 units  of  
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HTIG should be given intramuscularly as 
soon as the diagnosis of tetanus is 
considered.1,9 The use of intrathecal HTIG is 
not indicated.1    
 
Management of muscle spasms 
Generalized spasms are life threatening. 
Patients should be placed in a quiet dark 
room to avoid provoking muscle spasms.  
Spasms can cause exhaustion when severe.   
Benzodiazepines are the mainstay in the 
symptomatic therapy of tetanus.  They are 
usually effective in controlling muscle 
spasms, and patients may benefit from their 
amnestic effect.  These drugs are gamma-
aminobutyric acid (GABA) agonists.  They 
have the potential of antagonizing the effect 
of the toxin.  
Treatment with diazepam, lorazepam, 
and midazolam appear to be equally 
effective. Oral administration of these drugs 
is possible, but some patients do not absorb 
the drugs well and develop gastrointestinal 
motility disorders. Diazepam 10 to 30 mg 
intravenously is the usual starting dose.  The 
intravenous formulation of diazepam and 
lorazepam contains propylene glycol that 
can cause lactic acidosis at high doses. 
Intravenous midazolam does not contain 
propylene glycol, but must be given as a 
continuous infusion of 5 to 15 mg/hour.   
Intravenous propofol infusion is 
effective in controlling spasms and rigidity.  
It is expensive and associated with lactic 
acidosis, hyper-triglyceridemia, and 
pancreatic dysfunction.1  
Neuromuscular blocking agents can be 
used in severe cases.  Pancuronium 
(intermittent injection) and the shorter acting 
vancuronium (continuous injection) are 
usually used.  Vancuronium is preferred 
over pancuronium because of the worsening 
of autonomic instability observed with the 
latter.  Both agents should be used 
cautiously and the patient should be sedated 
adequately.  These agents should be stopped 
daily to assess the patient’s progress, and to 
observe for possible complications.  
Intrathecal baclofen was found to control 
spasms and rigidity in a few small studies.10  
 
Management of autonomic instability  
Magnesium sulfate is effective in the 
treatment of autonomic dysfunction in 
patients with tetanus.1,11  It also has a 
potential role in controlling muscle spasms.  
Magnesium sulfate blocks cathecholamine 
release from the nerves and reduces receptor 
responsiveness to cathecholamine.  
Labetolol (0.25 to 1 mg/min) could be 
used because of its dual alpha and beta 
blocking properties.1 Beta blockade alone 
should be avoided because the resulting 
unopposed alpha effect may produce severe 
hypertension and even death. Other useful 
agents include morphine sulfate by 
continuous intravenous infusion, atropine, 
and clonidine.   
   
Supportive Care 
Patients with tetanus are at risk of 
respiratory failure and aspiration.  Many 
require endotracheal intubation to maintain 
adequate ventilation and preserve the 
airway.1 Early tracheostomy usually is 
preferred in patients with tetanus who 
develop respiratory failure because of the 
likelihood of prolonged mechanical 
ventilation.  
Nutritional support should be started as 
soon as possible because energy demands 
and protein requirements are very high.  
Physical therapy should be started as soon as 
the spasms have ceased. 
 
Active Immunization 
Tetanus is one of the rare bacterial 
infections that do not confer immunity 
following recovery.  All patients with 
tetanus should receive active immunization 
with three doses of tetanus and diphtheria 
toxoids spaced at least two weeks apart, with 
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the first dose administered upon diagnosis.  
It should be presumed that patients who are 
inadequately immunized to tetanus are 
inadequately immunized to diphtheria as 
well.12  Subsequent doses should be given at 
10-year intervals throughout adulthood. 
 
Prophylaxis 
Tetanus is a preventable disease.1 A 
series of three monthly intramuscular 
injections of tetanus toxoid provides 
adequate immunity for at least 5 years. 
Patients younger than 7 years of age and 
those never immunized to pertussis should 
receive the combined diphtheria-tetanus-
pertussis vaccine (Tdap). Tetanus-diphteria 
(Td) booster injections are indicated every 
10 years.  Mild reaction to tetanus toxoid is 
common including local tenderness, edema, 
and low grade fever. Severe reactions are 
rare. Guillain-Barre syndrome was linked to 
tetanus toxoid in some reports but this was 
not confirmed in subsequent epidemiologic 
analysis.1 
The CDC13 has recommended adminis-
tering tetanus toxoid-containing vaccine and 
tetanus immune globulin (TIG) as part of 
standard wound management to prevent 
tetanus (see Table 1). Tdap is preferred to 
Td for adults vaccinated less than five years 
earlier who require a tetanus toxoid-
containing vaccine as part of wound 
management and who have not received 
Tdap previously. For adults previously 
vaccinated with Tdap, Td should be used if a 
tetanus toxoid-containing vaccine is 
indicated for wound care. Adults who have 
completed the 3-dose primary tetanus 
vaccination series and have received a 
tetanus toxoid-containing vaccine less than 
five years earlier are protected against 
tetanus and do not require a tetanus toxoid-
containing vaccine as part of wound 
management. 
Persons with unknown or uncertain 
tetanus vaccination histories should be 
considered to have had no previous tetanus 
toxoid-containing vaccine. Persons who 
have not completed the primary series might 
require tetanus toxoid and passive 
vaccination with TIG at the time of wound 
management (see Table 1). When both TIG 
and a tetanus toxoid-containing vaccine are 
indicated, each product should be 
administered using a separate syringe at 
different anatomic sites. Adults with a 
history of Arthus reaction following a 
previous dose of a tetanus toxoid-containing 
vaccine should not receive a tetanus toxoid-
containing vaccine until at least 10 years 
after the most recent dose, even if they have 
a wound that is neither clean nor minor. In 
all circumstances, the decision to administer 
TIG is based on the primary vaccination 
history for tetanus (see Table 1). 
 
 
Table 1.  Recommendation for use of tetanus prophylaxis in wound management. 
Clean, minor wounds All other wounds  
Immunization with 
tetanus toxoid Tetanus toxoid Immunoglobulin Tetanus toxoid Immunoglobulin 
Unknown or less than 
three doses  
Yes No Yes Yes 
Three or more doses No, unless >10 
years since last 
dose 
No No unless > 5 
years since last 
dose 
No 
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